Download PDF Flyer
Impact Factor Current: 0.953
5 - Year: 0.789

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Latest Issue: Volume 16 , Issue 11 , 2019

Back Journal Home
Impact Factor
Web of Science Impact Factor

Current: 0.953
5 - Year: 0.789

Ranking & Category

  • 55th of 59 in Chemistry, Medicinal

Topics Covered

1 Topics

View
Covered Diseases

0 Diseases

View

Aims & Scope

Letters in Drug Design & Discovery publishes letters, mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.

Abstracted/Indexed in


Science Citation Index ExpandedTM, Journal Citation Reports/Science Edition, InCites, Chemistry Citation Index®, Current Contents®/Physical, Chemical and Earth Sciences, ISI Alerting Service, Scopus, EMBASE, Chemical Abstracts Service/SciFinder, TOC Premier, ProQuest, ChemWeb, Google Scholar, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub, Index Copernicus, J-Gate, CNKI Scholar, Suweco CZ, Ulrich's Periodicals Directory and JournalTOCs.

Endorsement(s)

"Letters in Drug Design & Discovery should be available in every library in the pharmaceutical industry and in universities."

R. F. Borne, Associate Director
Laboratory for Applied Drug Design and Synthesis, The University of Mississippi, USA

Authors' Comments

I would like to thank Bentham Science Publishers for their peerless effort to keep up scientists and students updated with the latest science and research work. Actually, Bentham assists researchers to achieve their goals to spread their reputation worldwide.
I have experienced sincere, efficient and effective communication while dealing with Bentham team members. I intend to submit my work to Bentham and try to pick up journals that match my research profile. I have submitted a recent work to Medicinal Chemistry and nowadays I am drafting a manuscript targeting Current Pharmaceutical Design. Honestly, no words neither sentences would express my gratefulness and admiration. Bentham has offered my institution three months trial to access their journal lists and surf on its Board. This free access trial fulfills my literature review and broadens my horizon to absorb the recent research in pharmaceutical sciences and medicinal chemistry. Finally, I wish Bentham more success and achievement!


Dima Sabbah
(Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.)


Has contributed: CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping and Synthesis.